Fundai

Osveh Pharmaceutical Company (DOSVE) cash flow statement

Operating, investing and financing cash flows, and the closing balance

Ticker
DOSVE
Industry
Pharmaceuticals
Market
Tehran Stock Exchange

Latest periods

Latest 9-month periods, in million rials
ItemTo 1405/06/31To 1404/06/31To 1403/06/31To 1402/09/30To 1401/09/30To 1400/09/30
Cash generated from operations2,876,9721,207,235630,628300,141980,1611,132,006
Cash payments for income tax-141,817-80,000-96,017-265,660-166,026-66,634
Net cash inflow (outflow) from operating activities2,735,1551,127,235534,61134,481814,1351,065,372
Cash payments for purchase of property, plant and equipment-89,336-50,058-89,354-271,732-508,285-201,555
Cash receipts from dividends82416,47650,0002176,362267,740
Cash receipts from interest on other investments9806,8033,9209551,111
Net cash inflow (outflow) from investing activities-88,414-34,432-32,551-165,34097,76538,633
Net cash inflow (outflow) before financing activities2,646,7411,092,803502,060-130,859911,9001,104,005
Cash payments for principal of loans-497,835-2,421,119-1,079,124-2,604,028-1,459,333-2,598,338
Cash payments for interest on loans-507,235-783,040-198,711-464,144-141,790-242,505
Cash payments for dividends-225,014-80,941-182,848-608,908-537,024-156,040
Net cash inflow (outflow) from financing activities-1,230,084-1,165,100-803,683297,820-738,147-941,883
Net increase (decrease) in cash1,416,657-72,297-301,623166,961173,753162,122
Cash balance at beginning of year183,207137,888460,121292,998105,73578,571
Effect of changes in exchange rates39,3590016202,316
Cash balance at end of year1,639,22365,591158,498460,121279,488243,009

Reporting periods

77 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.